UrologyNews.net

Urology Xagena

Xagena Mappa
Medical Meeting
Onco News
Pneumobase.it

Initial results from the phase 1 clinical trial EV-103 were announced. Forty-five patients were evaluated for safety with the combination of the investigational agent Enfortumab Vedotin and the immune ...


Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy ( BKI ) released a study investigating the use of combination checkpoint immunotherapy ...


For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a higher likelihood of being diagnosed with Alzheimer's disease or dementia, compared to ...


Although bladder cancer is a fairly rare cancer type, representing an estimated 4.6% of new cancer cases in 2019, it is the most common malignancy of the urinary system, with high recurrence rate and ...


Results from the phase 3 TITAN study were presented in an oral session at the American Society of Clinical Oncology (ASCO ) Annual Meeting in Chicago, and simultaneously published in The New England ...


Activation of FGFR signaling is involved in a variety of malignancies including advanced urothelial cancer. Rogaratinib is an oral pan-FGFR kinase inhibitor. Results from a phase I expansion co ...


ADXS-PSA, an attenuated Listeria monocytogenes-based immunotherapy that targets prostate-specific antigen ( PSA ), is designed to generate antigen-specific T cell effectors that kill tumor cells. Pu ...


Anti-PD1 treatment with Pembrolizumab ( Keytruda ) is a promising treatment strategy in many solid tumors. Researchers have reported clinical outcomes of adding Pembrolizumab to men with metastatic ...


Cabozantinib ( Cabometyx ) has shown robust clinical activity in advanced clear cell renal cell carcinoma ( RCC ). Non-clear cell renal cell carcinoma ( nccRCC ), a heterogeneous mix of diseases, ha ...


Radium-223 dichloride ( Ra-233; Xofigo ), a bone targeting alpha radiopharmaceutical, and Enzalutamide ( Xtandi ), are approved for metastatic castration refractory prostate cancer ( mCRPC ). Per SW ...


The phase 3 PROSPER trial has showed a statistically significant improvement in metastasis-free survival ( MFS ) with Enzalutamide ( Xtandi; n = 933 ) versus placebo ( n = 468 ) in asymptomatic men wi ...


Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic progression-free survival ( rPFS ) with Olaparib ( Lynparza ) in ...


Although immune checkpoint inhibitors ( ICI ) have improved outcomes in some patients with Platinum-resistant metastatic urothelial carcinoma ( mUC ), many patients ( eg, patients with TCGA luminal 1 ...


New findings were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ) in San Francisco, and were simultaneously published in The New England Journal of M ...


Over the past decade, several systemic agents as Docetaxel, Cabazitaxel, Sipuleucel-T, Abiraterone and Enzalutamide have improved overall survival ( OS ) in metastatic prostate cancer ( mPCa ) patient ...